• Je něco špatně v tomto záznamu ?

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

U. Reuter, C. Lucas, D. Dolezil, AL. Hand, MD. Port, RM. Nichols, C. Stroud, A. Tockhorn-Heidenreich, HC. Detke

. 2021 ; 38 (11) : 5465-5483. [pub] 20210920

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003255

INTRODUCTION: Results from the open-label extension of the phase 3b CONQUER trial are presented to evaluate the effectiveness and safety of galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, for up to 6 months in patients with multiple prior migraine preventive treatment failures. METHODS: Patients were 18-75 years old with episodic or chronic migraine and 2-4 standard-of-care migraine preventive medication category failures. After 3 months of randomized treatment with galcanezumab (120 mg/month with 240 mg loading dose; n = 232) or placebo (n = 230), patients entered a 3-month open-label extension (120 mg/month galcanezumab with a blinded 240 mg loading dose for previous-placebo patients). Primary efficacy measure was mean change from double-blind baseline in monthly migraine headache days. RESULTS: A total of 432/449 patients (96%) who entered open-label treatment completed the study. Mean change in monthly migraine headache days in the total population, which was - 1.3 for placebo and - 4.4 for galcanezumab patients at the end of double-blind treatment (p < 0.001), was - 5.2 and - 5.6, respectively, at the end of open-label treatment with galcanezumab. Among patients with episodic migraine, mean change in monthly migraine headache days had been - 0.6 for placebo and - 2.8 for galcanezumab after double-blind treatment (p < 0.001) and was - 4.5 and - 3.8, respectively, after open-label treatment. Among patients with chronic migraine, mean change in monthly migraine headache days had been - 2.5 for placebo and - 6.6 for galcanezumab after double-blind treatment (p < 0.001) and was - 6.5 and - 8.2, respectively, after open-label treatment. Adverse events were similar to those observed during double-blind placebo treatment. Review of data in elderly patients (65-75 years of age) indicated that galcanezumab was well tolerated in this age group, with no safety issues identified. CONCLUSIONS: Galcanezumab was effective and safe during open-label treatment in patients who had experienced failures of previous migraine preventives. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03559257.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003255
003      
CZ-PrNML
005      
20220127150524.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-021-01911-7 $2 doi
035    __
$a (PubMed)34542830
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Reuter, Uwe $u Charité Universitätsmedizin Berlin, Berlin, Germany
245    10
$a Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial / $c U. Reuter, C. Lucas, D. Dolezil, AL. Hand, MD. Port, RM. Nichols, C. Stroud, A. Tockhorn-Heidenreich, HC. Detke
520    9_
$a INTRODUCTION: Results from the open-label extension of the phase 3b CONQUER trial are presented to evaluate the effectiveness and safety of galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, for up to 6 months in patients with multiple prior migraine preventive treatment failures. METHODS: Patients were 18-75 years old with episodic or chronic migraine and 2-4 standard-of-care migraine preventive medication category failures. After 3 months of randomized treatment with galcanezumab (120 mg/month with 240 mg loading dose; n = 232) or placebo (n = 230), patients entered a 3-month open-label extension (120 mg/month galcanezumab with a blinded 240 mg loading dose for previous-placebo patients). Primary efficacy measure was mean change from double-blind baseline in monthly migraine headache days. RESULTS: A total of 432/449 patients (96%) who entered open-label treatment completed the study. Mean change in monthly migraine headache days in the total population, which was - 1.3 for placebo and - 4.4 for galcanezumab patients at the end of double-blind treatment (p < 0.001), was - 5.2 and - 5.6, respectively, at the end of open-label treatment with galcanezumab. Among patients with episodic migraine, mean change in monthly migraine headache days had been - 0.6 for placebo and - 2.8 for galcanezumab after double-blind treatment (p < 0.001) and was - 4.5 and - 3.8, respectively, after open-label treatment. Among patients with chronic migraine, mean change in monthly migraine headache days had been - 2.5 for placebo and - 6.6 for galcanezumab after double-blind treatment (p < 0.001) and was - 6.5 and - 8.2, respectively, after open-label treatment. Adverse events were similar to those observed during double-blind placebo treatment. Review of data in elderly patients (65-75 years of age) indicated that galcanezumab was well tolerated in this age group, with no safety issues identified. CONCLUSIONS: Galcanezumab was effective and safe during open-label treatment in patients who had experienced failures of previous migraine preventives. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03559257.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    12
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a migréna $x farmakoterapie $x prevence a kontrola $7 D008881
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lucas, Christian $u Hôpital Salengro, CHU de Lille, Lille, France
700    1_
$a Dolezil, David $u DADO MEDICAL, Prague, Czech Republic
700    1_
$a Hand, Austin L $u IQVIA, Durham, NC, 27703, USA
700    1_
$a Port, Martha D $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA
700    1_
$a Nichols, Russell M $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA
700    1_
$a Stroud, Chad $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA
700    1_
$a Tockhorn-Heidenreich, Antje $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA
700    1_
$a Detke, Holland C $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. detke_holland_c@lilly.com
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 38, č. 11 (2021), s. 5465-5483
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34542830 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150521 $b ABA008
999    __
$a ok $b bmc $g 1750879 $s 1154404
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 38 $c 11 $d 5465-5483 $e 20210920 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace